A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)

🧪 Interventions in This Study

• INCA033989 (DRUG)
• Ruxolitinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

• Royal Brisbane and Women'S Hospital — Herston, Queensland
• Royal Adelaide Hospital — Adelaide, South Australia
• Peter Maccallum Cancer Centre — Melbourne, Victoria
• The Alfred Hospital — Melbourne, Victoria
• Princess Margaret Cancer Center — Toronto, Ontario
• Hopital Maisonneuve-Rosemont, Montreal, Qc — Montreal, Quebec
• Sjaellands Universitetshospital — Roskilde,
• Vejle Hospital — Vejle,
• Institut Bergonie — Bordeaux,
• Chu Nimes — Nîmes,
• Hospital Saint Louis — Paris,
• Institut Gustave Roussy — Villejuif,
• University Medical Center Rwth Aachen — Aachen,
• Universitatsklinikum Halle (Saale) — Halle,
• Universitätsklinikum Ulm — Ulm,
• Aou Policlinico S. Orsola-Malpighi — Bologna,
• Azienda Ospedaliero-Universitaria Careggi (Aouc) — Florence,
• Fondazione Irccs Ca Granda Ospedale Maggiore — Milan,
• National Cancer Center Hospital East — Chiba-ken,
• Kagoshima University Hospital — Kagoshima,
• Osaka Metropolitan University Hospital — Osaka,
• Nippon Medical School Hospital — Tokyo,
• Mie University Hospital — Tsu,
• Hospital Universitario 12 de Octubre — Madrid,
• Hospital Universitari I Politecnic La Fe — Valencia,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myeloproliferative Neoplasms

• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — Birmingham, Alabama
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — Duarte, California
• Study of INCA036978 in Participants With Myeloproliferative Neoplasms — Birmingham, Alabama
• Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation — Chicago, Illinois
• A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms — Phoenix, Arizona

Explore by condition: All Myeloproliferative Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.